Alcohol Consumption Emerges as a Key Risk Factor for Buccal Cancer in India
December 24, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Miostat
(United States) [Available]Synonyms :
carbachol
Class :
cholinergic agonists and Ophthalmic glaucoma agents
Brand Name :
Miostat
(United States) [Available]Synonyms :
carbachol
Class :
cholinergic agonists and Ophthalmic glaucoma agents
Dosage Forms & Strengths
Topical solution
1.5%
3%
Intraocular solution
0.01%
Instill not more than 0.5 ml into the anterior chamber during surgery
Instill not more than 0.5 ml into the anterior chamber during surgery
Dosage Forms & Strengths
Topical solution
1.5%
3%
Intraocular solution
0.01%
Instill not more than 0.5 ml into the anterior chamber during surgery
Instill not more than 0.5 ml into the anterior chamber during surgery
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
It may diminish the metabolism when combined with Choline esters
It may diminish the metabolism when combined with Choline esters
It may diminish the metabolism when combined with Choline esters
It may diminish the metabolism when combined with Choline esters
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
may have an increased adverse effect when combined with cholinergic agonists
it may increase the risk of adverse effects of cholinergic agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
it may enhance the risk of adverse effects of Cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
acetylcholinesterase inhibitors may enhance the adverse/toxic effect of cholinergic Agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may decrease the toxic effect of beta blockers
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may decrease the anticholinergic effect of cholinergic agonists
may increase the toxic effect of anti-cholinergic agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the toxic effect of Acetylcholinesterase Inhibitors
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
could increase the adverse or toxic effect
may have an increasingly adverse effect when combined with cholinergic agonists
The parasympathomimetic carbamoylcholine functions as an agonist of nicotinic and muscarinic receptors.
Miosis results from intraocular administration, which also increases aqueous humor outflow to lower intraocular pressure.
It induces miosis in the eye by activating cholinergic receptors.
Adverse drug reactions:
Frequency Not Defined
Corneal clouding
Bullous keratopathy
Persistent bullous keratopathy
Retinal detachment
Abdominal cramps
Postoperative iritis following cataract extraction
Epigastric distress
Flushing
Arrhythmia
Hypotension
Syncope
Epigastric stress
Salivation
Headache
Sweating
Tightness in urinary bladder
Vomiting
Asthma
Diaphoresis
None
Contraindication:
Hypersensitivity
Acute iritis
Caution:
asthma,
acute heart failure,
corneal abrasion
Use caution when administering general anesthesia to patients.
The natural rubber (latex) used in the vial stopper has the potential to trigger serious allergic responses.
Pregnancy warnings:
AU TGA pregnancy category: B2
US FDA pregnancy category: C
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
It has a longer duration of action and noticeable effects 24 hours after treatment because it is more resistant to acetylcholinesterase hydrolysis than other choline esters.
It decreases the activity of the extraocular muscles of convergence, causes the ciliary body, iris, and conjunctiva’s blood vessels to dilate, and increases the blood-aqueous barrier’s permeability, all of which might result in ocular inflammation and vascular congestion.
Topical solution:
Apply finger pressure to the lacrimal sac after administration to lessen outflow to the nose and throat and wipe away extra solution from the hand and eye.
Intraocular Injection:
Withdraw the recommended amount using a 21-gauge needle and a 0.45-micron filter supplied by the manufacturer into a sterile disposable syringe.
Replace the syringe’s connected needle and filter with an appropriate atraumatic cannula for intraocular irrigation before administration.
The instillation should be mild, tangential to the pupil border, and parallel to the iris face.
Patient information leaflet
Generic Name: carbachol
Why do we use carbachol?
Carbachol is used to induce miosis for surgery and to reduce intraocular pressure after cataract surgery.
It is also used in managing inhibition of perioperative intraocular pressure.
It is mainly effective in patients those are refractory or hypersensitive to pilocarpine.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
